{"entity":{"id":"profoundbio","kind":"company","name":"ProfoundBio","aka":[],"tldr":"ProfoundBio developed antibodies that deliver a chemotherapy drug to ovarian cancer cells carrying a protein called folate receptor alpha. Genmab bought the company for 1.8 billion dollars in 2024.","summary":"ProfoundBio was a privately owned, clinical-stage Seattle biotech developing next-generation antibody-drug conjugates and ADC linker-payload technology. Its lead asset rinatabart sesutecan (Rina-S) is a folate receptor alpha (FRα)-targeted topoisomerase 1 inhibitor ADC designed to treat a broader FRα-expressing population than first-generation FRα ADCs; at acquisition it was in the phase 2 portion of a phase 1/2 trial in ovarian cancer and other FRα-expressing solid tumours, and had received FDA Fast Track designation in January 2024 for FRα-expressing platinum-resistant ovarian cancer. Genmab agreed in April 2024 to acquire ProfoundBio for USD 1.8 billion in cash, gaining three clinical-stage candidates and the ADC platforms; the deal closed in May 2024 and the ProfoundBio domain now redirects to genmab.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.genmab.com/"},{"label":"Genmab acquisition announcement (Nasdaq copy)","url":"https://www.nasdaq.com/press-release/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["adcs"],"technologies":["adc","topoisomerase-inhibitors"],"targets":["folr1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["profoundbio.com redirects to genmab.com, recorded as the website. Pre-acquisition venture rounds (reported elsewhere as a 2023 Series B) not sourced and omitted. ir.genmab.com returned HTTP 403 to my fetches."],"hq":"Seattle, WA","country":"US","companyType":"biotech","website":"https://www.genmab.com/","stage":"acquired","investors":["medicxi"],"funding":[{"round":"Acquisition","year":2024,"amountUsd":1800000000,"source":"https://www.nasdaq.com/press-release/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of-profoundbio","note":"All-cash deal announced 3 April 2024; Nasdaq copy of the Genmab company announcement"}],"acquiredBy":"genmab"},"route":"/companies/profoundbio/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}],"company":[{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"},{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/"}]}}